



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan *et al.*
Serial No.: 09/709,905
Filed: November 10, 2000
For: *USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG
DESIGN AND CLINICAL APPLICATIONS*
Art Unit: 1631
Examiner: Unassigned

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

08/10/01
Date

Kelly Fischer
Kelly Fischer

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), and the cited reference for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

(X) The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By: *[Signature]*
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24737-1906C
Address all correspondence to:
Stephanie L. Seidman, Esq.
Heller Ehrman White & McAuliffe LLP
4350 La Jolla Village Drive
San Diego, California 92122-1246
Telephone: 858/450-8403
Facsimile: 858/587-5360
EMAIL sseidman@HEWM.com


RECEIVED

AUG 15 2001

TECH CENTER 1600/2900

RECEIVED

AUG 15 2001



TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RAMNARAYAN *et al.*

Serial No.: 09/709,905

Filed: November 10, 2000

For: *USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG
DESIGN AND CLINICAL APPLICATIONS*

Art Unit: 1631

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

08/10/01
Date

Kelly Fischer
Kelly Fischer
#12
Plunkett
2/27/02

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Form PTO-1449 (1 page) is provided herewith.

The document listed on the Form PTO-1449 and supplied herewith is in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98,



RECEIVED

AUG 15 2001

TECH CENTER 1600/2900

U.S.S.N. 09/709,905

RAMNARAYAN *et al.*


Supplemental Information Disclosure Statement

as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing reference and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By: 
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24737-1906C
Address all correspondence to:
Heller Ehrman White & McAuliffe LLP
4350 La Jolla Village Drive
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL sseidman@HEWM.com